David W. Dube
President chez Stock Car Stocks Mutual Fund, Inc.
Profil
Mr. David W.
Dube, CPA, is a Director at Glycogenesys, Inc., President at Stock Car Stocks Mutual Fund, Inc., and Chairman & Chief Financial Officer at Swan Group of Cos., Inc. He is on the Board of Directors at Glycogenesys, Inc.
Mr. Dube also served on the board at CNE Group, Inc.
He received his undergraduate degree from Suffolk University, a graduate degree from Suffolk University, and a graduate degree from Bentley University.
Postes actifs de David W. Dube
| Sociétés | Poste | Début |
|---|---|---|
| Stock Car Stocks Mutual Fund, Inc. | President | 23/12/2009 |
Anciens postes connus de David W. Dube
| Sociétés | Poste | Fin |
|---|---|---|
| CNE Group, Inc. | Directeur/Membre du Conseil | 14/11/2005 |
| SWAN GROUP OF COMPANIES, INC. | Président | - |
Glycogenesys, Inc.
 Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | - |
Formation de David W. Dube
| Bentley University | Graduate Degree |
| Suffolk University | Graduate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Entreprise privées | 4 |
|---|---|
| CNE Group, Inc. | Commercial Services |
Glycogenesys, Inc.
Glycogenesys, Inc. Miscellaneous Commercial ServicesCommercial Services GlycoGenesys, Inc., a biotechnology company, develops novel pharmaceutical products based on carbohydrate compounds and related technologies. The company's lead drug candidate GCS-100, a treatment for various forms of solid tumors and bloodborne cancers, completed a Phase II (a) clinical trial for pancreatic cancer, and also completed a Phase II (a) clinical trial for colorectal cancer. The company focuses on the development of carbohydrate-based pharmaceutical products and related technologies in connection with oncology. It was founded in 1992 and is headquartered in Boston, MA. | Commercial Services |
| Stock Car Stocks Mutual Fund, Inc. | Miscellaneous |
Swan Group of Cos., Inc.
 Swan Group of Cos., Inc. Wholesale DistributorsDistribution Services Swan Group of Companies, Inc. engages in the manufacture and sale of smokeless cigarette products. The company was founded on January 24, 1996 and is headquartered in Largo, FL. | Distribution Services |